No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NERV Minerva Neurosciences
- 2.5000
- +0.0400+1.63%
Close May 22 16:00 ET
- 2.4000
- -0.1000-4.00%
Pre 05:02 ET
17.48MMarket Cap-564P/E (TTM)
2.5450High2.3796Low11.64KVolume2.4100Open2.4600Pre Close29.00KTurnover0.21%Turnover RatioLossP/E (Static)6.99MShares13.490052wk High-0.48P/B13.58MFloat Cap2.286452wk Low--Dividend TTM5.43MShs Float126.7200Historical High--Div YieldTTM6.72%Amplitude1.2600Historical Low2.4900Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.
Minerva Neurosciences Is Maintained at Neutral by HC Wainwright & Co.
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences (NASDAQ:NERV) with a Neutral and lowers the price target from $11 to $7.
Minerva Neurosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 197.87% HC Wainwright & Co. $11 → $7 Maintains Neutral 02/27/2024 368.09% HC Wainwright & Co. →
Express News | Minerva Neurosciences, Inc. : H.c. Wainwright Cuts Target Price to $7 From $11
Express News | Minerva Neurosciences Inc - Qtrly Net Loss per Share of $1.13 Basic and Diluted
Comments
$Minerva Neurosciences(NERV.US$
Roluperidone NDA receives CRL from FDA 🙁
⚠️ FDA cited clinical deficiencies:
▪️ Insufficient substantial evidence of effectiveness
▪️ lacks data on concomitant antipsychotic admin.
▪️ lacks data to establish change in negative symptoms of schizophrenia
▪️ inadequate number of subjects exposed at proposed dose
ℹ️Add'l info on Roluperidone…
⇒ for negative symptoms of schizophrenia
⇒ NDA
⇒ PDUFA: 02/26/24
Roluperidone NDA receives CRL from FDA 🙁
⚠️ FDA cited clinical deficiencies:
▪️ Insufficient substantial evidence of effectiveness
▪️ lacks data on concomitant antipsychotic admin.
▪️ lacks data to establish change in negative symptoms of schizophrenia
▪️ inadequate number of subjects exposed at proposed dose
ℹ️Add'l info on Roluperidone…
⇒ for negative symptoms of schizophrenia
⇒ NDA
⇒ PDUFA: 02/26/24
3
1
$Minerva Neurosciences(NERV.US$ sold for some profit now
1
$Minerva Neurosciences(NERV.US$ bounce 🚀🚀🚀
1
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg